These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 11487257)
1. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Fujimoto J; Sakaguchi H; Aoki I; Khatun S; Tamaya T Br J Cancer; 2001 Aug; 85(3):313-6. PubMed ID: 11487257 [TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153 [TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150 [TBL] [Abstract][Full Text] [Related]
4. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115 [TBL] [Abstract][Full Text] [Related]
6. [Expression of vascular endothelial growth factor and microvessel density in ovarian tumor]. Qi SY Ai Zheng; 2003 Mar; 22(3):320-3. PubMed ID: 12654197 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Stimpfl M; Tong D; Fasching B; Schuster E; Obermair A; Leodolter S; Zeillinger R Clin Cancer Res; 2002 Jul; 8(7):2253-9. PubMed ID: 12114428 [TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021 [TBL] [Abstract][Full Text] [Related]
9. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Fujimoto J; Aoki I; Toyoki H; Khatun S; Sato E; Sakaguchi H; Tamaya T Oncology; 2004; 66(5):420-8. PubMed ID: 15331930 [TBL] [Abstract][Full Text] [Related]
10. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598 [TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Lutgendorf SK; Johnsen EL; Cooper B; Anderson B; Sorosky JI; Buller RE; Sood AK Cancer; 2002 Aug; 95(4):808-15. PubMed ID: 12209725 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining. Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466 [TBL] [Abstract][Full Text] [Related]
13. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Nishida N; Yano H; Komai K; Nishida T; Kamura T; Kojiro M Cancer; 2004 Sep; 101(6):1364-74. PubMed ID: 15368324 [TBL] [Abstract][Full Text] [Related]
16. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. Bao LH; Sakaguchi H; Fujimoto J; Tamaya T J Biomed Sci; 2007 May; 14(3):373-81. PubMed ID: 17219251 [TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]. Peng XP; Li JD; Li MD; Ye XM; Yan WC Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072 [TBL] [Abstract][Full Text] [Related]
18. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Ng IO; Poon RT; Lee JM; Fan ST; Ng M; Tso WK Am J Clin Pathol; 2001 Dec; 116(6):838-45. PubMed ID: 11764072 [TBL] [Abstract][Full Text] [Related]